Welcome to KAHR Medical

KAHR Medical ("KAHR") is an Immuno-Oncology drug development company and our mission

is to develop novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune

diseases. KAHR's drug development pipeline is built around the 'Dual Signaling Proteins (DSP)'

technology; Harnessing the power of the TNF Superfamily (regulators of the immune system) for

treatment of disease. DSPs are a unique class of novel therapeutic agents that possess two

functional ends. The DSP technology is divided into two proprietary platforms; the DSP-Hexamers

and the DSP-Clusters, each covering hundreds of drug candidates. KAHR actively operates two 

drug-development programs, KAHR-101 and KAHR-102, representing proof-of-concept for its

two proprietary platforms.

News & Events

February 15, 2016: KAHR Medical Completes a $15M Series B Private Equity Financing

December 12, 2015: KAHR Medical Reports Raising $12M At First Closing Of Its Series B Private Equity Financing

December 6, 2015: KAHR Medical presents KAHR-102 pre-clinical data at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

December 1, 2015: KAHR obtains regulatory approval to start a Phase-I/IIa clinical trial with KAHR-102 in lymphoma patients. Trial to start in Israel in mid 2016.

October 13, 2015: KAHR obtains final reports of toxicology studies for KAHR-102. Studies show KAHR-102 is well tolerated in mice and monkeys.

August 22, 2015: Prof. Arnold Freedman from Harvard Medical School joins KAHR's Scientific Advisory Board. Professor Freedman is the Clinical Director of the Lymphoma Program at the Dana-Farber Cancer Institute and a leading expert on lymphoma drug clinical development  

June 28, 2015: KAHR Medical submits IND-equivalent file to Israeli regulatory authorities to study KAHR-102 in lymphoma patients as part of a Phase-I/IIa clinical trial